BR112015021756A8 - método para fazer uma formulação estável alergênica - Google Patents

método para fazer uma formulação estável alergênica Download PDF

Info

Publication number
BR112015021756A8
BR112015021756A8 BR112015021756A BR112015021756A BR112015021756A8 BR 112015021756 A8 BR112015021756 A8 BR 112015021756A8 BR 112015021756 A BR112015021756 A BR 112015021756A BR 112015021756 A BR112015021756 A BR 112015021756A BR 112015021756 A8 BR112015021756 A8 BR 112015021756A8
Authority
BR
Brazil
Prior art keywords
peanut
allergen
make
stable formulation
flour
Prior art date
Application number
BR112015021756A
Other languages
English (en)
Other versions
BR112015021756A2 (pt
BR112015021756B1 (pt
Inventor
Walser Bryan
V Raff Howard
Original Assignee
Aimmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015021756(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aimmune Therapeutics Inc filed Critical Aimmune Therapeutics Inc
Publication of BR112015021756A2 publication Critical patent/BR112015021756A2/pt
Publication of BR112015021756A8 publication Critical patent/BR112015021756A8/pt
Publication of BR112015021756B1 publication Critical patent/BR112015021756B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

resumo fabricação de formulações de amendoim para desensibilização oral o presente pedido refere-se a um método para gerenciar o processo de desenvolvimento e fabricação de uma formulação terapeuticamente eficaz. proteínas de amendoim são caracterizadas de farinha de amendoim e formulações encapsuladas feitas usando a farinha de amendoim para imuno terapia oral de alergias a amendoim. 1/1
BR112015021756-7A 2013-03-14 2014-03-12 Método para fazer uma formulação estável alergênica BR112015021756B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784964P 2013-03-14 2013-03-14
US61/784,964 2013-03-14
PCT/US2014/024401 WO2014159607A1 (en) 2013-03-14 2014-03-12 Manufacture of peanut formulations for oral desensitization

Publications (3)

Publication Number Publication Date
BR112015021756A2 BR112015021756A2 (pt) 2017-07-18
BR112015021756A8 true BR112015021756A8 (pt) 2019-11-19
BR112015021756B1 BR112015021756B1 (pt) 2023-01-10

Family

ID=51528061

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021756-7A BR112015021756B1 (pt) 2013-03-14 2014-03-12 Método para fazer uma formulação estável alergênica

Country Status (18)

Country Link
US (5) US9198869B2 (pt)
EP (3) EP2968529B1 (pt)
JP (3) JP6752140B2 (pt)
CN (2) CN109125283A (pt)
AU (5) AU2014240404B2 (pt)
BR (1) BR112015021756B1 (pt)
CA (1) CA2903229A1 (pt)
DK (2) DK3482771T3 (pt)
ES (2) ES2940686T3 (pt)
FI (2) FI3482771T3 (pt)
FR (1) FR23C1026I1 (pt)
HK (1) HK1217660A1 (pt)
HU (1) HUE051831T2 (pt)
MX (1) MX2015010315A (pt)
PL (1) PL2968529T3 (pt)
PT (1) PT2968529T (pt)
SI (1) SI2968529T1 (pt)
WO (1) WO2014159607A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
DK3482771T3 (da) * 2013-03-14 2023-03-20 Nestle Sa Fremstilling af jordnøddeformuleringer til oral desensibilisering
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2016033094A1 (en) 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US10064936B2 (en) 2015-02-20 2018-09-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂ａ及過敏原調配物
US10856567B2 (en) 2016-07-22 2020-12-08 Kari Brown Baby food products containing allergenic proteins and methods of delivering same
ES2950506T3 (es) * 2016-12-05 2023-10-10 Reacta Biotech Ltd Formulaciones de alimentos para pruebas alimentarias orales
CA3050093A1 (en) * 2017-01-13 2018-07-19 Aimmune Therapeutics, Inc. Methods of manufacture of nut flours and formulations for oral immunotherapy
BR102017026619A2 (pt) 2017-02-15 2018-10-30 Euroimmun Medizinische Labordiagnostika Ag ensaio melhorado para a diagnose de alergia a amendoim
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
GB201718342D0 (en) * 2017-11-06 2017-12-20 Cambridge Allergy Ltd Allergenic protein formulations for immunotherapy
CA3107667A1 (en) 2018-07-27 2020-01-30 Aimmune Therapeutics, Inc. Oral immunotherapy unit dose dispensing systems and methods
CA3122854A1 (en) * 2018-12-17 2020-06-25 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN113891722A (zh) * 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
EP4009959A1 (en) * 2019-08-08 2022-06-15 Evonik Operations GmbH Method of preparing a solid dosage form and a lubricant
EP4081251A4 (en) * 2019-12-23 2024-03-20 Prota Therapeutics Pty Ltd PHARMACEUTICAL COMPOSITIONS
CA3204515A1 (en) 2021-01-08 2022-07-14 Jamie M. Orengo Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2023198674A1 (en) 2022-04-11 2023-10-19 Alk-Abelló A/S Peanut allergen composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) * 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
WO1992015285A1 (en) 1991-03-01 1992-09-17 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) * 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) * 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
DK1272213T3 (da) 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
MXPA05009079A (es) 2003-02-28 2006-05-19 Alk Abello As Forma de dosificacion que tiene una matriz de sacarido.
US7820175B2 (en) * 2004-03-19 2010-10-26 Herbal Spring, Llc Herbal therapy for the treatment of food allergy
CA2634094A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
MX2011005168A (es) 2008-11-19 2011-05-30 Avantor Performance Mat Inc Excipiente basado en celulosa microcristalina granular, directamente compresible, procesos de fabricacion y uso del mismo.
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
CN101912364B (zh) * 2010-08-09 2015-07-15 刘会梅 银杏内酯b脂质体组合药物
GB201104537D0 (en) 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
ES2936312T3 (es) * 2011-08-31 2023-03-16 Perosphere Tech Inc Métodos para la desensibilización eficaz y rápida de pacientes alérgicos
WO2013087119A1 (en) * 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
DK3482771T3 (da) 2013-03-14 2023-03-20 Nestle Sa Fremstilling af jordnøddeformuleringer til oral desensibilisering
US9492535B2 (en) * 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
WO2016033094A1 (en) 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
CA3050093A1 (en) 2017-01-13 2018-07-19 Aimmune Therapeutics, Inc. Methods of manufacture of nut flours and formulations for oral immunotherapy
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy

Also Published As

Publication number Publication date
AU2022201858A1 (en) 2022-04-07
FI3482771T3 (fi) 2023-04-03
US11141352B2 (en) 2021-10-12
HK1217660A1 (zh) 2017-01-20
BR112015021756A2 (pt) 2017-07-18
AU2016231523B2 (en) 2018-05-31
CN105101994A (zh) 2015-11-25
JP7454519B2 (ja) 2024-03-22
US20230120350A1 (en) 2023-04-20
US20180042816A1 (en) 2018-02-15
JP2016512537A (ja) 2016-04-28
WO2014159607A1 (en) 2014-10-02
CN105101994B (zh) 2018-10-12
JP6752140B2 (ja) 2020-09-09
ES2826224T3 (es) 2021-05-17
AU2014240404B2 (en) 2016-07-21
US20200129378A1 (en) 2020-04-30
DK2968529T3 (da) 2020-10-12
AU2014240404A1 (en) 2015-09-17
EP3482771A1 (en) 2019-05-15
US9198869B2 (en) 2015-12-01
BR112015021756B1 (pt) 2023-01-10
JP2021073321A (ja) 2021-05-13
EP2968529A4 (en) 2016-10-05
FIC20230022I1 (fi) 2023-07-04
FR23C1026I1 (fr) 2023-10-06
AU2018222980A1 (en) 2018-09-20
SI2968529T1 (sl) 2021-03-31
US10449118B2 (en) 2019-10-22
AU2020202685A1 (en) 2020-05-14
EP3482771B1 (en) 2023-01-18
PT2968529T (pt) 2020-11-10
AU2020202685B2 (en) 2022-01-20
CA2903229A1 (en) 2014-10-02
JP2019108357A (ja) 2019-07-04
CN109125283A (zh) 2019-01-04
ES2940686T3 (es) 2023-05-10
HUE051831T2 (hu) 2021-03-29
EP3998080A1 (en) 2022-05-18
DK3482771T3 (da) 2023-03-20
JP6891205B2 (ja) 2021-06-18
AU2022201858B2 (en) 2024-04-04
AU2016231523A1 (en) 2016-10-06
PL2968529T3 (pl) 2021-04-19
EP2968529B1 (en) 2020-08-05
EP2968529A1 (en) 2016-01-20
US20160030289A1 (en) 2016-02-04
MX2015010315A (es) 2016-04-13
US20140271836A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015021756A8 (pt) método para fazer uma formulação estável alergênica
WO2014144952A3 (en) Modulators of the eif2alpha pathway
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CY1122951T1 (el) Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
BR112015029788A2 (pt) hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
BR112015003591A8 (pt) Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
EP3084748A4 (en) Display device using semiconductor light emitting device and method of fabricating the same
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112015029462A2 (pt) Inibidores de quinase
BR112017008707A8 (pt) Ração de pré-mistura para aquacultura encapsulada
BR112014015526A2 (pt) processo de fabricação de triazinona-benzoxazinonas e uso de uma amino-benzoxazinona
EP2968449A4 (en) Modification and novel compositions of human secretoglobin proteins
WO2013188774A3 (en) Skin care formulations including octapeptide complexes and methods for their manufacture
BR112015028986A2 (pt) métodos para produzir partículas compreendendo proteínas terapêuticas
CL2017003284A1 (es) Una molécula de ácidos nucleicos para conferir propiedades insecticidas a las plantas.
BR112017016626A2 (pt) micro-organismo com capacidade para produzir ácido quinólico e método para produzir ácido quinólico com o uso do micro-organismo
EP3046937A4 (en) Modified anti-inflammatory proteins and method of use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: AIMMUNE THERAPEUTICS, INC. (US)

B25A Requested transfer of rights approved

Owner name: SOCIETE DES PRODUITS NESTLE S.A. (CH)